SEC F	Form 4
-------	--------

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	o
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

			or Section 30(h) of the Investment Company Act of 1940						
L. Name and Address of Reporting Person <sup>*</sup> Sussman Joel F.		Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol Galera Therapeutics, Inc. [GRTX]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Sussiliali Jo</u>	<u>ci i.</u>				Director	10% Owner			
		2. Data of Farliant Transaction (Manth/Day/Maar)	X	Officer (give title below)	Other (specify below)				
(Last) (First) (Middle) C/O GALERA THERAPEUTICS, INC.,			3. Date of Earliest Transaction (Month/Day/Year) 01/31/2020		Chief Accounting Officer				
2 W LIBERTY	7 BLVD #100								
(Ctro ot)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Fili	ng (Check Applicable			
Street) MALVERN	PA	19355		X	Form filed by One Re	porting Person			
	PA	19555			Form filed by More the Person	an One Reporting			
(City)	(State)	(Zip)							

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transa Code ( 8)	ction	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	of (D) (li 3, 4 and (A)		Date Expiration Tate Tate Tate Tate Tate Tate Tate Tate		Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$14.84	01/31/2020		A		49,263		(1)	01/30/2030	Common Stock	49,623	\$0.00	49,623	D	

**Explanation of Responses:** 

1. The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 31, 2020.

Remarks:

### <u>/s/ J. Mel Sorensen, Attorney-</u> in-Fact for Joel F. Sussman

02/04/2020

\*\* Signature of Reporting Person

ng Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.